Skip to main content
Top
Published in: Breast Cancer 5/2016

01-09-2016 | Original Article

Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer

Authors: Ichiro Maeda, Kayoko Abe, Hirotaka Koizumi, Chika Nakajima, Shinya Tajima, Hiromi Aoki, Junichi Tsuchiya, Seiko Tsuchiya, Kyoko Tsuchiya, Arata Shimo, Koichiro Tsugawa, Takahiko Ueno, Shinobu Tatsunami, Masayuki Takagi

Published in: Breast Cancer | Issue 5/2016

Login to get access

Abstract

Background

In recent papers, Ki67 labeling index (LI) has been used to classify breast cancer patients into the low and high Ki67LI groups for comparison studies, which showed significant differences in many prognostic factors. It has not been clarified whether image analysis software can be used for calculating LI in breast cancer. In our study, we examined whether Ki67LI in breast cancer calculated using image analysis software correlates with that measured on the basis of visual.

Methods

Fifty patients were randomly selected among breast cancer patients who underwent surgical operation from March, 2010 to May, 2010 in our hospital without preoperative chemotherapy. In this study, for the virtual slide system (VSS: VS120-L100, Olympus, Tokyo, Japan), the high-resolution VSs of all the 50 patients were prepared as samples. The image analysis software use for calculating LI was Tissuemorph Digital Pathology (Tissuemorph DP: Visiopharm, Hoersholm, Denmark). The calculated LI was extracted from 3 to 5 views containing hot spots. The LI calculated using Tissuemorph DP was designed as LI/image/T. The digital image of 3 to 5 LI/image/T views was printed out, and on the digital photograph, we counted visually the number of Ki67-immunopositive cells in exactly the same area, and the percentage of Ki67-immunopositive cells was designed as LI/direct. Moreover, a pathologist’s assistant (PA) determined the tumor area in the same specimen using VSS and calculated LI using Tissuemorph DP, which was designed as LI/image/PA. The chief pathologist (CP) similarly calculated LI which was designed as LI/image/CP. We evaluated the degree of agreement between different data sets “LI/image/T and LI/direct” and “LI/image/T, LI/image/CP, and LI/image/PA” by using interclass correlation coefficient (ICC).

Results

The average counts of cells were as follows: LI/direct, 3209.7 ± 1970.4 (SD); LI/image/T, 2601.6 ± 1697.1; LI/image/PA, 2886.5 ± 2027.5; LI/image/CP, 18805.5 ± 22293.4. The values of LI/direct and LI/image/T showed almost perfect agreement as showed by an ICC of 0.885 (95 % CI, 0.806–0.933; p < 0.001). The agreement among three investigators was almost perfect. The obtained ICC was 0.825 (95 % CI, 0.739–0.890; p < 0.001) among the data of LI/image/T, LI/image/CP and LI/image/PA. There were five cases that immunopositivity for Ki67 showed a more than 10 % disagreement between LI/direct and LI/image/T.

Conclusion

The merits of calculating Ki67 LI using Tissuemorph DP are as follows. First, the staining intensity of the cells to be counted can be adjusted. Second, the portion of a tumor including “hot spots” for counting can be chosen. Third, many cancer cells can be counted more rapidly using Tissuemorph DP than by visual observation. However, it is important that pathologist should check and carry out the final decision of the data, when Ki67 LI using Tissuemorph DP is calculated.
Literature
1.
go back to reference Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, et al. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res. 2011;17(24):7828–34.CrossRefPubMed Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, et al. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res. 2011;17(24):7828–34.CrossRefPubMed
2.
go back to reference Millar EK, Graham PH, McNeil CM, Browne L, O’Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 2011;105(2):272–80.CrossRefPubMedPubMedCentral Millar EK, Graham PH, McNeil CM, Browne L, O’Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 2011;105(2):272–80.CrossRefPubMedPubMedCentral
3.
go back to reference Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26(34):5569–75.CrossRefPubMedPubMedCentral Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26(34):5569–75.CrossRefPubMedPubMedCentral
4.
go back to reference Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS ONE. 2013;8(3):e55901.CrossRefPubMedPubMedCentral Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, Fourquet A, Pierga JY, Cottu P, Dieras V, et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS ONE. 2013;8(3):e55901.CrossRefPubMedPubMedCentral
5.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral
6.
go back to reference Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J, Matsubara O. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol. 2013;13:5.CrossRefPubMedPubMedCentral Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J, Matsubara O. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol. 2013;13:5.CrossRefPubMedPubMedCentral
7.
go back to reference Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, Voorhorst F, Baak JP. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61(6):1134–44.CrossRefPubMed Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, Voorhorst F, Baak JP. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61(6):1134–44.CrossRefPubMed
8.
go back to reference Haglund F, Ma R, Huss M, Sulaiman L, Lu M, Nilsson IL, Hoog A, Juhlin CC, Hartman J, Larsson C. Evidence of a functional estrogen receptor in parathyroid adenomas. J Clin Endocrinol Metab. 2012;97(12):4631–9.CrossRefPubMed Haglund F, Ma R, Huss M, Sulaiman L, Lu M, Nilsson IL, Hoog A, Juhlin CC, Hartman J, Larsson C. Evidence of a functional estrogen receptor in parathyroid adenomas. J Clin Endocrinol Metab. 2012;97(12):4631–9.CrossRefPubMed
9.
go back to reference Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007;20(12):1307–15.CrossRefPubMed Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007;20(12):1307–15.CrossRefPubMed
10.
go back to reference Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Soiland H, Baak JP. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 2010;23(12):1567–76.CrossRefPubMed Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Soiland H, Baak JP. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 2010;23(12):1567–76.CrossRefPubMed
11.
go back to reference Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104:1539–43.CrossRefPubMed Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104:1539–43.CrossRefPubMed
12.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed
13.
go back to reference Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N, Yoshida K, Kadoya T, Tamaki K, Kumaki N et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer (Tokyo, Japan) 2014. Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N, Yoshida K, Kadoya T, Tamaki K, Kumaki N et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer (Tokyo, Japan) 2014.
14.
go back to reference Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, Akslen LA. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS ONE. 2014;9(11):e112121.CrossRefPubMedPubMedCentral Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, Akslen LA. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS ONE. 2014;9(11):e112121.CrossRefPubMedPubMedCentral
Metadata
Title
Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer
Authors
Ichiro Maeda
Kayoko Abe
Hirotaka Koizumi
Chika Nakajima
Shinya Tajima
Hiromi Aoki
Junichi Tsuchiya
Seiko Tsuchiya
Kyoko Tsuchiya
Arata Shimo
Koichiro Tsugawa
Takahiko Ueno
Shinobu Tatsunami
Masayuki Takagi
Publication date
01-09-2016
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0634-7

Other articles of this Issue 5/2016

Breast Cancer 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine